From Fragile to Resilient: Building Pharma Supply Chains that Withstand Global Shocks [2025 Report]

To gauge how prepared pharmaceutical companies were for the impact of the potential tariff changes, STAEDEAN conducted a targeted industry survey earlier this year. A total of 130 pharma professionals across the U.S. and Europe responded, representing organizations of all sizes.

The lesson? Cost efficiency alone is no longer enough. Agility, visibility, and resilience have become essential. According to the report:

• Almost 70% of pharma companies cite sourcing APIs and raw materials as their biggest vulnerability.
• 56% of APIs come from China and 42% from India, exposing companies to tariff risk, political shifts, and logistical bottlenecks.
• Supplier qualification can stretch beyond five months for a third of companies - time the industry doesn’t always have in a disruption